0. DOCID:28642 SCORE: 0.00279742518057137
DOCNO: 15350945
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: pathology
QUALIFIER: therapy
AUTHOR: Henry Q Xiong HQ
AUTHOR: James L Abbruzzese JL
AFFILIATION: Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Surgical oncology clinics of North America.
COUNTRY: United States
TITLE: Adjuvant therapy for pancreatic cancer: current status and future directions.
PUBDATE: 20041001
This article summarizes the important past and ongoing adjuvant therapy trials for pancreatic cancer. The recent developments in the fields of radiosensitization, chemotherapy, and molecular-targeted therapy are outlined. Finally, the future study strategies for adjuvant therapy trials are discussed.


1. DOCID:29582 SCORE: 0.00267545561060353
DOCNO: 12663955
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Reproductive Medicine
QUALIFIER: therapy
AUTHOR: Helena Davies H
AUTHOR: Diana Greenfield D
AUTHOR: William Ledger W
AFFILIATION: Academic Unit of Child Health, Sheffield University, Sheffield Children's Hospital, Western Bank, Sheffield S10 2TH, UK.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Human fertility (Cambridge, England)
COUNTRY: England
TITLE: Reproductive medicine in a late effects of cancer clinic.
PUBDATE: 20030201
This review discusses the most commonly observed problems in young people who have survived childhood cancer, with particular emphasis on the issues of fertility. It also describes the role of the late effects clinic in transitional care and the multidisciplinarity of the clinicians required to meet the needs of these young people. There is a need for evidence-based guidelines for management of long-term survivors.


2. DOCID:31107 SCORE: 0.00265512673401437
DOCNO: 15775352
OWNER: NLM
STATUS: PubMed-not-MEDLINE
AUTHOR: Toshio Okano T
AUTHOR: Kimie Nakagawa K
AFFILIATION: Kobe Pharmaceutical University, Department of Hygienic Science.
PUBTYPE: Journal Article
JOURNALTITLE: Clinical calcium.
COUNTRY: Japan
TITLE: [Novel vitamin d analogues with selective biological activities]
PUBDATE: 20020501
1alpha,25-dihydroxyvitamin D(3) (1alpha,25 (OH)(2)D(3)) is a naturally occuring organic compound showing strong calcemic activity and anti-proliferative/differentiation-inducing activity. 1alpha,25 (OH)(2)D(3) is expected to be a therapeutic agent for metabolic bone diseases and cancer treatment. To enhance its selectivity, specificity, and safety as a therapeutic agent, it is required to separate its calcium-regulating activity from its non-calcium-regulating activity. For this reason, a variety of vitamin D analogues have been developed. The analogues with modification of A-ring are promising candidates for this purpose.


3. DOCID:30173 SCORE: 0.00255627659300647
DOCNO: 15239339
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: antagonists & inhibitors
QUALIFIER: drug therapy
AUTHOR: Pascal Eschwege P
AFFILIATION: Service d'Urologie, Hôpital Bicêtre, Faculté de Médecine Paris-Sud Département de Chirurgie, Institut Gustave-Roussy, avenue Camille-Desmoulins, 94805 Villejuif.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Bulletin du cancer.
COUNTRY: France
TITLE: [Cyclooxygenase 2 inhibitors and urologic and gynaecologic cancers]
PUBDATE: 20040501
PGE2 is one of the most important prostaglandin involved in the oncogenesis. PGE2 is found at high concentration level in the most of epithelial cancer. Urologic and gynaecologic cancer express the enzyme which are at the origin of PGE2: cyclooxygenase 2. Cox2 inhibitors present anticancer properties demonstrated in wide varieties of cellular and animal models. Human applications are currently tested in many clinical trials for bladder, prostate and uterine carcinomas.


4. DOCID:30664 SCORE: 0.00244346142744965
DOCNO: 12185221
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: A Leslie A
AUTHOR: R J C Steele RJ
AFFILIATION: Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Postgraduate medical journal.
COUNTRY: England
TITLE: Management of colorectal cancer.
PUBDATE: 20020801
Colorectal cancer is the second most common cause of cancer death in the UK. Prompt investigation of suspicious symptoms is important, but there is increasing evidence that screening for the disease can produce significant reductions in mortality. High quality surgery is of paramount importance in achieving good outcomes, particularly in rectal cancer, but adjuvant radiotherapy and chemotherapy have important parts to play. The treatment of advanced disease is still essentially palliative, although surgery for limited hepatic metastases may be curative in a small proportion of patients.


5. DOCID:30674 SCORE: 0.00244346079827088
DOCNO: 11977537
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: DNA-Binding Proteins
QUALIFIER: genetics
AUTHOR: Seiichi Takenoshita S
AUTHOR: Kenichi Takita K
AFFILIATION: Department of Surgery II, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Gan to kagaku ryoho. Cancer & chemotherapy.
COUNTRY: Japan
TITLE: [Hereditary non-polyposis colorectal cancer (HNPCC)]
PUBDATE: 20020401
Hereditary non-polyposis colorectal cancer (HNPCC) is a type of hereditary colorectal cancer with autosomal dominant traits. Its causal genes are mismatch repair genes such as the hMSH2 and hMLH1 genes. Owing to its frequency, juvenile onset, and the outbreaks of multiple colorectal cancers and cancers occurring over multiple organs, it is recognized as a very important disease for the purpose of understanding not only colorectal cancers, but also other digestive cancers, and furthering pathological inquiry into the state of cancers in general.


6. DOCID:30675 SCORE: 0.00244346028629631
DOCNO: 12147429
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: epidemiology
AUTHOR: Clare Sansom C
AUTHOR: Geoffrey Mutuma G
PUBTYPE: Journal Article
JOURNALTITLE: The lancet oncology.
COUNTRY: England
TITLE: Kenya faces cancer challenge.
PUBDATE: 20020801
The world's population is predicted to increase from 6.1 billion to 9.3 billion people over the next 50 years. Cancer burden is also set to increase with the ageing population and currently there are about 10.1 million people who have been diagnosed with neoplastic disease. By 2020, this number is expected to increase to 20 million. Perhaps disturbingly, 70% of people with cancer are thought to live in the developing world, which has only 5% of the world's resources. In this reportage, Clare Sansom and Geoffrey Mutuma, formerly Kenya's chief government pathologist, investigate the way in which this African country is facing these challenges.


7. DOCID:29380 SCORE: 0.00224304716316845
DOCNO: 12772513
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Immunotherapy
QUALIFIER: biosynthesis
QUALIFIER: pharmacology
QUALIFIER: immunology
QUALIFIER: therapy
QUALIFIER: immunology
QUALIFIER: therapy
QUALIFIER: immunology
QUALIFIER: therapy
AUTHOR: Evangelia Razis E
AUTHOR: George Fountzilas G
AFFILIATION: First Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Thessaloniki, Macedonia, Greece.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Technology evaluation: TriGem, Titan.
PUBDATE: 20030401
Titan (formerly Trilex) is developing TriGem, a monoclonal antibody directed against I17, for the potential treatment of advanced cancers that express the GD2 ganglioside, including melanoma, small-cell lung cancer, neuroblastoma and sarcoma. Phase II trials of TriGem for use in advanced melanoma were ongoing by June 2002. TriGem also has potential for the treatment of psoriasis, for which phase II trials had begun by 1996.


8. DOCID:30923 SCORE: 0.00222499088266697
DOCNO: 16024952
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: secondary
QUALIFIER: radionuclide imaging
QUALIFIER: radionuclide imaging
QUALIFIER: diagnostic use
QUALIFIER: diagnostic use
QUALIFIER: radionuclide imaging
AUTHOR: Nataraj Shanmugam N
AUTHOR: William Johns W
AUTHOR: Kelly Chasse K
AUTHOR: Shiv M Gupta SM
AFFILIATION: Division of Nuclear Medicine, Danbury, CT, USA.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Clinical nuclear medicine.
COUNTRY: United States
TITLE: Serendipitous detection of metastatic thyroid cancer during I-123 Tc-99m sestamibi dual parathyroid imaging.
PUBDATE: 20050801
Dual isotope parathyroid imaging performed on a 47-year-old man with known papillary thyroid cancer and biochemical hyperparathyroidism showed residual concentration of sestamibi consistent with a right inferior parathyroid adenoma. Subsequent thyroidectomy and parathyroidectomy was performed. Histology revealed a left superior parathyroid adenoma and normal right inferior parathyroid gland. Right inferior parathyroid adenoma on scintigraphy was, in fact, a cervical lymph node metastasis from the papillary thyroid carcinoma.


9. DOCID:31894 SCORE: 0.00221992900026063
DOCNO: 15122249
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: immunology
QUALIFIER: methods
AUTHOR: Carl G Figdor CG
AUTHOR: I Jolanda M de Vries IJ
AUTHOR: W Joost Lesterhuis WJ
AUTHOR: Cornelis J M Melief CJ
AFFILIATION: Department of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, University Medical Center Nijmegen, PO Box 9101, 6500HB Nijmegen, The Netherlands. c.figdor@ncmls.kun.nl
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature medicine.
COUNTRY: United States
TITLE: Dendritic cell immunotherapy: mapping the way.
PUBDATE: 20040501
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.


10. DOCID:29577 SCORE: 0.0021676265630354
DOCNO: 12837240
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: Richard O Hynes RO
AFFILIATION: Howard Hughes Medical Institute, Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. rohynes@mit.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cell.
COUNTRY: United States
TITLE: Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both?
PUBDATE: 20030601
Metastasis is a rare event. Does it arise from rare, variant, highly metastatic cells or does a primary tumor progress to a premalignant state from which metastases arise stochastically without further changes in gene expression? Arguments and evidence have been adduced to support either position. A paper in this month's Cancer Cell and other arguments instead suggest models combining features of both.


11. DOCID:31307 SCORE: 0.00215181199361929
DOCNO: 12607580
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Palliative Care
DESCRIPTOR: Stents
QUALIFIER: therapy
AUTHOR: David C Madoff DC
AUTHOR: Michael J Wallace MJ
AFFILIATION: Vascular and Interventional Radiology Section, Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. dmadoff@di.mdacc.tmc.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Surgical oncology clinics of North America.
COUNTRY: United States
TITLE: Palliative treatment of unresectable bile duct cancer: which stent? which approach?
PUBDATE: 20021001
Nonsurgical options for the palliative treatment of unresectable bile duct cancer are discussed. Despite all of the available approaches, the disease remains uniformly fatal. The goal of managing unresectable bile duct cancer is to treat the symptoms that still contribute to significant morbidity and mortality. Further development of new treatment strategies and modalities is needed to improve the quality of life and survival of patients with this disease.


12. DOCID:30997 SCORE: 0.00209625150808177
DOCNO: 12109346
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: pathology
QUALIFIER: diagnosis
AUTHOR: Martha K Terris MK
AFFILIATION: Section of Urology (112C), Veterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304, USA. mterris@stanford.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Urologic clinics of North America.
COUNTRY: United States
TITLE: Prostate biopsy strategies: past, present, and future.
PUBDATE: 20020201
Endorectal sonography for prostatic imaging was first described in 1968 and gained wide acceptance, particularly since the 1980s. Presently, extended biopsies consist of the sextant biopsy pattern plus various combinations of anteriorly directed biopsies and posterolateral sampling that includes the anterior horn of the peripheral zone. The cancer detection rate for transrectal ultrasound-guided prostate biopsies has fallen, and the repeat biopsy rate has risen. The future will most likely see fewer biopsies performed but with wiser guiding systems.


13. DOCID:31672 SCORE: 0.00204044160750765
DOCNO: 14992944
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: Souheil Boubia S
AUTHOR: Françoise Lepimpec Barthes FL
AUTHOR: Claire Danel C
AUTHOR: Marc Riquet M
AFFILIATION: Departments of Thoracic Surgery and Pathology, Georges Pompidou European Hospital, Paris, France.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Annals of thoracic surgery.
COUNTRY: United States
TITLE: Peripheral intrapulmonary lymph node metastases of non-small-cell lung cancer.
PUBDATE: 20040301
Since the development and progress of computed tomographic imaging, peripheral intrapulmonary lymph nodes (IPLNs) have become increasingly described and well-known entities. Intrapulmonary lymph nodes may appear as a solitary pulmonary nodular shadow mimicking a non-small-cell lung cancer (NSCLC) or as multiple nodules masquerading as carcinoma metastases. We describe a case in which IPLNs presented as a clinical "nodular" T4 N0 NSCLC that finally proved to be a pathologic T2 N1 NSCLC, thus raising new questions on this entity.


14. DOCID:29285 SCORE: 0.00197759289929393
DOCNO: 16266571
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: methods
QUALIFIER: methods
AUTHOR: Søren R Rafaelsen SR
AFFILIATION: Vejle Sygehus, Røntgenafdelingen, Vejle. rafaelsen@dadlnet.dk
PUBTYPE: Journal Article
JOURNALTITLE: Ugeskrift for laeger.
COUNTRY: Denmark
TITLE: [Diagnostic imaging in staging of colorectal cancer]
PUBDATE: 20051001
The main strength of MR is the ability to define the mesorectal facia. There is recent evidence suggesting that MR imaging can accurately predict the tumor-free circumferential resection margin before total mesorectal excision. However, the prediction of T stage is less accurate and more affected by the experience of the observer. Transrectal ultrasonography has proven useful for staging of rectal carcinoma. Computed tomography is one of the most useful imaging techniques for the evaluation of metastatic lesions in colorectal cancer.